Recently, a low-dose metronomic cyclophosphamide regimen was reported to stimulate NK-dependent antitumor immunity and promote cytokine production, reducing tumor angiogenesis through Treg depletion.[25] Incubation of human NK cells with paclitaxel resulted in a dose-dependent reduction in cytotoxicity against tumor cell lines, as well as peripheral blood mononuclear cells (PBMCs), MHC-unrestricted T cells and CTLs.[25] There is much evidence about the ability of NK cells to reduce the progression of multiple myeloma. This evidence concerns the gene HLA-C and neoplasm.